Actionable news
All posts from Actionable news
Actionable news in ACOR: Acorda Therapeutics, Inc.,

Acorda Stroke Study Fails, Dampening Revenue Growth Plans

Acorda Therapeutics (ACOR) shares are trading lower Monday after the company's latest failed attempt to expand the use of its top-selling drug Ampyra.

A mid-stage study of Ampyra in patients with walking difficulties following a stroke "did not show sufficient efficacy" to support further clinical development, Acorda said Monday.

The company's stock fell 9% to $19.30 per share in early Monday...